Enanta Pharmaceuticals Inc (ENTA)

42.90 -0.04  -0.09% NASDAQ Nov 27, 20:00 USD
View Full Chart
Price Chart
View All Events

Events

Date Type Description
02/05/2021 Earnings Enanta Pharmaceuticals Inc First Quarter Earnings for 2021 Release
02/05/2021 16:30 EST Misc Enanta Pharmaceuticals Inc First Quarter Earnings Conference Call for 2021
11/25/2020 Misc Enanta Pharmaceuticals Inc Annual Report for 2020
11/23/2020 Earnings Enanta Pharmaceuticals Inc Fourth Quarter Earnings Result for 2020
11/23/2020 16:30 EST Misc Enanta Pharmaceuticals Inc Fourth Quarter Earnings Conference Call for 2020
08/04/2020 16:30 EDT Misc Enanta Pharmaceuticals Inc Third Quarter Earnings Conference Call for 2020
08/04/2020 Earnings Enanta Pharmaceuticals Inc Third Quarter Earnings Result for 2020
05/06/2020 16:30 EDT Misc Enanta Pharmaceuticals Inc Second Quarter Earnings Conference Call for 2020
05/06/2020 Earnings Enanta Pharmaceuticals Inc Second Quarter Earnings Result for 2020
02/26/2020 Misc Enanta Pharmaceuticals Inc Annual General Meeting for 2019
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: http://www.enanta.com
  • Investor Relations URL: http://ir.enanta.com/phoenix.zhtml?c=147990&p=irol-irhome
  • HQ State/Province: Massachusetts
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Small Cap/Blend
  • Next Earnings Release: Feb. 05, 2021
  • Last Earnings Release: Nov. 23, 2020
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

Top Fund Holders

Symbol Name Weighting
SMHCIX ST Healthcare Innovations 9 RE 2.77%
BBP Virtus LifeSci Biotech Products ETF 1.96%
F000014EGP ST Healthcare Innovations 8 CA 1.96%
GERM ETFMG Treatments Testing and Adv ETF 0.82%

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.